Linden Thomas Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Linden Thomas Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-176,004	Closed	-$5.53M	–	553
2026 Q2	$5.53M	Buy	176,004 +12,413	+8%	+$366K	0.45%	42
2026 Q1	$4.05M	Buy	163,591 +23,693	+17%	+$564K	0.39%	63
2025 Q4	$3.27M	Buy	139,898 +4,317	+3%	+$96.2K	0.33%	78
2025 Q3	$2.67M	Buy	135,581 +8,155	+6%	+$168K	0.27%	108
2025 Q2	$2.77M	Buy	127,426 +92,193	+262%	+$2.18M	0.3%	90
2025 Q1	$854K	Buy	35,233 +2,594	+8%	+$58.4K	0.11%	302
2024 Q4	$681K	Buy	32,639 +5,732	+21%	+$123K	0.09%	347
2024 Q3	$535K	Buy	26,907 +5,581	+26%	+$103K	0.07%	370
2024 Q2	$330K	Buy	21,326 +4,583	+27%	+$71.3K	0.05%	395
2024 Q1	$267K	Buy	16,743 +5,666	+51%	+$85.4K	0.04%	396
2023 Q4	$186K	Buy	+11,077	New	+$151K	0.03%	412

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Linden Thomas Advisory Services's CPRX Position: Q3 2026 in Review

Linden Thomas Advisory Services sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 176,004 shares — an estimated $5.53M sold.

Linden Thomas Advisory Services first reported a position in CPRX in Q4 2023 and held it in 11 quarters. The position peaked at $5.53M in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

Linden Thomas Advisory Services reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Linden Thomas Advisory Services sold 176,004 Catalyst Pharmaceutical shares in Q3 2026, an estimated $5.53M.
Linden Thomas Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 11 quarters.
Linden Thomas Advisory Services's Catalyst Pharmaceutical position peaked at $5.53M in Q2 2026.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.